<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00893594</url>
  </required_header>
  <id_info>
    <org_study_id>113010</org_study_id>
    <nct_id>NCT00893594</nct_id>
  </id_info>
  <brief_title>Efficacy of Sumatriptan With Naprosyn in Migraine With Aura</brief_title>
  <official_title>A Parallel Two Arm, Double Blinded Placebo Study, Examining the Efficacy of Sumatriptan With Naprosyn in the Treatment of Migraine With Aura</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dent Neurologic Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dent Neurologic Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blinded placebo study, examining the efficacy of Sumatriptan with Naprosyn
      in the treatment of migraine with aura.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2010</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary outcome measure will be comparative percentage of patients pain free at 2 and 4 hours from initiating treatment with placebo vs treatment with Treximet (sumatriptan with naprosyn).</measure>
    <time_frame>2 and 4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary outcomes will be percentage of patients with pain relief at 2 and 4 hours.</measure>
    <time_frame>2 and 4 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Migraine With Aura</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo taken at onset of aura associated with migraine.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sumatriptan with naprosyn taken at onset of aura associated with migraine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sumatriptan with naprosyn</intervention_name>
    <description>Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Treximet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must be 18 to 50 years of age, inclusive.

          -  Patients will meet the International Headache Society (IHS) classification criteria
             for migraine with aura.

          -  Subjects must carry the diagnosis of 1-2 migraine with aura per month for at least
             three months before study inclusion. and migraine with aura were included in the study

          -  Subjects must have an onset of a visual aura that occurs 15-30 minutes before a
             migraine headache.

          -  Subjects must be able to understand and complete a migraine diary.

          -  Subjects must be able to distinguish a migraine with aura from other types of
             headache.

          -  Subjects must be in generally good health as confirmed by medical and medication
             history, baseline physical and neurological exam and vital signs.

          -  Female subjects must be either a) postmenopausal for one year, b)surgically sterile,
             c) practicing acceptable birth control for at least one month prior to screening and
             throughout study, or d) practicing abstinence and agree to continue same throughout
             study.

        Exclusion Criteria:

          -  Subjects who have a significant systemic disease other than migraine that is equally
             painful or more painful.

          -  Subjects who have other progressive neurological disorders.

          -  Subjects who have more than 8 migraines or 15 headache days per month.

          -  Subjects who have previously taken Treximet and failed due to lack of efficacy or
             adverse side effects.

          -  Subjects who carry the diagnosis of chronic tension type headache or cluster headache
             based on the International Headache Society criteria.

          -  Subject should not have received any other investigative drug within 3 months prior to
             enrollment in the study.

          -  Subject who have the diagnosis of seizure disorder, chronic daily headache,
             uncontrolled hypertension, cardiovascular disease, history of stroke, basilar or
             hemiplegic migraine, hepatic disease, or active peptic ulcer disease.

          -  Subjects currently taking or in 3 months prior to study, use of prophylactic migraine
             medications.

          -  Subjects who have a known allergy to Sumatriptan or Naprosyn.

          -  Subjects who in the opinion of Dr. Mechtler have a condition for which they should not
             be enrolled in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laszlo L Mechtler, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dent Neurologic Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mary K Betz, MS</last_name>
    <phone>716-250-2000</phone>
    <email>mbetz@dentinstitute.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rebecca Hogan, BS</last_name>
    <phone>716-558-5670</phone>
    <email>rhogan@dentinstitute.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Dent Neurologic Institute</name>
      <address>
        <city>Amherst</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca M Hogan, BS</last_name>
      <phone>716-558-5670</phone>
      <email>rhogan@dentinstitute.com</email>
    </contact>
    <contact_backup>
      <last_name>Mary K Betz, P.A.</last_name>
      <phone>716-558-5662</phone>
      <email>mbetz@dentinstitute.com</email>
    </contact_backup>
    <investigator>
      <last_name>Laszlo L Mechtler, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>February 18, 2015</last_update_submitted>
  <last_update_submitted_qc>February 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Dent Neurologic Institute</investigator_affiliation>
    <investigator_full_name>Mary Kay Betz, MS RPA-C</investigator_full_name>
    <investigator_title>Physician Assistant</investigator_title>
  </responsible_party>
  <keyword>migraine</keyword>
  <keyword>migraine with aura</keyword>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

